biom’up announced enrollment of first patient in clinical investigation of HEMOBLAST Bellows

biom’up announced the enrollment of the first patient in their prospective, randomized, controlled, multicenter, pivotal, clinical investigation evaluating the safety and efficacy of HEMOBLAST™ Bellows in Cardiothoracic, Abdominal, and Orthopedic Lower Extremity Surgeries.

HEMOBLAST™ Bellows is an investigational device, not currently for sale in the US that is intended for use in surgical procedures as an adjunct to hemostasis when control of bleeding by conventional procedures is ineffective or impractical.

Since its formation in 2005, biom’up has been developing medical devices based on patent protected biopolymers. Using this experience, biom’up has created innovative and clinically proven products that cover many different surgical specialties – orthopedics, spinal, cardiac, general, and maxillo-facial and dental. biom’up is committed to the design and development of novel high-performing solutions for a better patient outcome.

biom’up
www.biomup.com

The post biom’up announced enrollment of first patient in clinical investigation of HEMOBLAST Bellows appeared first on MassDevice.

from MassDevice http://ift.tt/2bWVlhj